Alternative splicing of CHEK2 and codeletion with NF2 promote chromosomal instability in meningioma

Neoplasia

Volumn 14, Issue 1, 2012, Pages 20-28

  Yang, Hong Wei ^a   Kim, Tae Min ^b   Song, Sydney S ^a   Shrinath, Nihal ^a   Park, Richard ^b   Kalamarides, Michel ^c,d   Park, Peter J ^b   Black, Peter M ^a   Carroll, Rona S ^a   Johnson, Mark D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Harvard Medical School Center for Biomedical Informatics   (United States)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; PROTEIN TYROSINE PHOSPHATASE;

ALTERNATIVE RNA SPLICING; ARTICLE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CENTROSOME; CHEK2 GENE; CHROMOSOMAL INSTABILITY; CHROMOSOME 22Q; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DNA REPAIR; GENE AMPLIFICATION; GENE DELETION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; MENINGIOMA; NF2 GENE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 84863056301     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.111574     Document Type: Article

References (34)

1. Hansson CM, Buckley PG, Grigelioniene G, Piotrowski A, Hellstrom AR, Mantripragada K, Jarbo C, Mathiesen T, and Dumanski JP (2007). Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus. BMC Genomics 8, 16.
2. Kalamarides M, Niwa-Kawakita M, Leblois H, Abramowski V, Perricaudet M, Janin A, Thomas G, Gutmann DH, and Giovannini M (2002). Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev 16, 1060-1065.
3. Lekanne Deprez RH, Bianchi AB, Groen NA, Seizinger BR, Hagemeijer A, van Drunen E, Bootsma D, Koper JW, Avezaat CJ, Kley N, et al. (1994). Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. Am J Hum Genet 54, 1022-1029.
4. Arslantas A, Artan S, Oner U, Durmaz R, Muslumanoglu H, Atasoy MA, Basaran N, and Tel E (2002). Comparative genomic hybridization analysis of genomic alterations in benign, atypical and anaplastic meningiomas. Acta Neurol Belg 102, 53-62.
5. Goutagny S, Yang HW, Zucman-Rossi J, Chan J, Dreyfuss JM, Park PJ, Black PM, Giovannini M, Carroll RS, and Kalamarides M (2010). Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res 16, 4155-4164.
6. Weber RG, Bostrom J, Wolter M, Baudis M, Collins VP, Reifenberger G, and Lichter P (1997). Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci USA 94, 14719-14724.
7. Lamszus K, Kluwe L, Matschke J, Meissner H, Laas R, and Westphal M (1999). Allelic losses at 1p, 9q, 10q, 14q, and 22q in the progression of aggressive meningiomas and undifferentiated meningeal sarcomas. Cancer Genet Cytogenet 110, 103-110.
8. Antoni L, Sodha N, Collins I, and Garrett MD (2007). CHK2 kinase: cancer susceptibility and cancer therapy-two sides of the same coin? Nat Rev Cancer 7, 925-936.
9. Yazaki T, Manz HJ, Rabkin SD, and Martuza RL (1995). Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 55, 4752-4756.
10. Ragel BT, Jensen RL, Gillespie DL, Prescott SM, and Couldwell WT (2007). Celecoxib inhibits meningioma tumor growth in a mouse xenograft model. Cancer 109, 588-597.
11. Cargioli TG, Ugur HC, Ramakrishna N, Chan J, Black PM, and Carroll RS (2007). Establishment of an in vivo meningioma model with human telomerase reverse transcriptase. Neurosurgery 60, 750-759, discussion 759-760.
12. Lee WH (1990). Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee. Neurosurgery 27, 389-395, discussion 396.
13. Tsai JC, Goldman CK, and Gillespie GY (1995). Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 82, 864-873.
14. Yang HW, Menon LG, Black PM, Carroll RS, and Johnson MD (2010). SNAI2/Slug promotes growth and invasion in human gliomas. BMC Cancer 10, 301.
15. Bell DW, Wahrer DC, Kang DH, MacMahon MS, FitzGerald MG, Ishioka C, Isselbacher KJ, Krainer M, and Haber DA (1999). Common nonsense mutations in RAD52. Cancer Res 59, 3883-3888.
16. Falck J, Lukas C, Protopopova M, Lukas J, Selivanova G, and Bartek J (2001). Functional impact of concomitant versus alternative defects in the Chk2-p53 tumour suppressor pathway. Oncogene 20, 5503-5510.
17. Chen Y and Poon RY (2008). The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability. Front Biosci 13, 5016-5029.
18. Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, et al. (2003). Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 72, 270-280.
19. Kilpivaara O, Alhopuro P, Vahteristo P, Aaltonen LA, and Nevanlinna H (2006). CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet 43, e34.
20. Staalesen V, Falck J, Geisler S, Bartkova J, Borresen-Dale AL, Lukas J, Lillehaug JR, Bartek J, and Lonning PE (2004). Alternative splicing and mutation status of CHEK2 in stage III breast cancer. Oncogene 23, 8535-8544.
21. Lemaire M, Prime J, Ducommun B, and Bugler B (2004). Evolutionary conservation of a novel splice variant of the Cds1/CHK2 checkpoint kinase restricted to its regulatory domain. Cell Cycle 3, 1267-1270.
22. Schwenzer NF, Bantleon R, Maurer B, Kehlbach R, Schraml C, Claussen CD, and Rodegerdts E (2007). Detection of DNA double-strand breaks using γH2AX after MRI exposure at 3 tesla: an in vitro study. J Magn Reson Imaging 26, 1308-1314.
23. Chehab NH, Malikzay A, Appel M, and Halazonetis TD (2000). Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 14, 278-288.
24. Yang S, Kuo C, Bisi JE, and Kim MK (2002). PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol 4, 865-870.
25. Castedo M, Perfettini JL, Roumier T, Yakushijin K, Horne D, Medema R, and Kroemer G (2004). The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene 23, 4353-4361.
26. Lingle WL, Lukasiewicz K, and Salisbury JL (2005). Deregulation of the centrosome cycle and the origin of chromosomal instability in cancer. Adv Exp Med Biol 570, 393-421.
27. Shreeram S, Hee WK, and Bulavin DV (2008). Cdc25A serine 123 phosphorylation couples centrosome duplication with DNA replication and regulates tumorigenesis. Mol Cell Biol 28, 7442-7450.
28. Ng HK, Lau KM, Tse JY, Lo KW, Wong JH, Poon WS, and Huang DP (1995). Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors. Neurosurgery 37, 764-773.
29. Vahteristo P, Eerola H, Tamminen A, Blomqvist C, and Nevanlinna H (2001). A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 84, 704-708.
30. Stracker TH, Couto SS, Cordon-Cardo C, Matos T, and Petrini JH (2008). Chk2 suppresses the oncogenic potential of DNA replication-associated DNA damage. Mol Cell 31, 21-32.
31. Fukasawa K (2008). P53, cyclin-dependent kinase and abnormal amplification of centrosomes. Biochim Biophys Acta 1786, 15-23.
32. Stolz A, Ertych N, Kienitz A, Vogel C, Schneider V, Fritz B, Jacob R, Dittmar G, Weichert W, Petersen I, et al. (2010). The CHK2-BRCA1 tumour suppressor pathway ensures chromosomal stability in human somatic cells. Nat Cell Biol 12, 492-499.
33. Ganem NJ, Godinho SA, and Pellman D (2009). A mechanism linking extra centrosomes to chromosomal instability. Nature 460, 278-282.
34. Carvalho LH, Smirnov I, Baia GS, Modrusan Z, Smith JS, Jun P, Costello JF, McDermott MW, Vandenberg SR, and Lal A (2007). Molecular signatures define two main classes of meningiomas. Mol Cancer 6, 64.